Culture

Why do psychiatric drugs help some, but not others? Study offers clues

When it comes to developing drugs for mental illnesses, three confounding challenges exist:

Men and women experience them differently, with things like depression and anxiety far more common in females.

A drug that works for one person may not work for another, and side effects abound.

New CU Boulder research, published in the journal eLIfe, sheds light on one reason those individual differences may exist. Turns out a key protein in the brain called AKT may function differently in males than females.

The study also offers a closer look at where, precisely, in the brain things may go wrong with it, marking an important step toward more targeted and less harmful therapies.

"The ultimate goal is to find the kink in the armor of mental illness - the proteins in the brain that we can specifically target without impacting other organs and causing side effects," says Charles Hoeffer, an assistant professor of integrative physiology at the Institute for Behavioral Genetics. "Personalization is also key. We need to stop hitting every mental illness with the same hammer."

Discovered in the 1970s and best known for its potential role in causing cancer when mutated, AKT has more recently been identified as a key player in promoting "synaptic plasticity." That's the brain's ability to strengthen connections between neurons in response to experience.

"Let's say you see a shark and you're scared and your brain wants to form a memory. You have to make new proteins to encode that memory," explains Hoeffer.

AKT is one of the first proteins to come online, cranking the gears up on a host of downstream proteins in that memory factory. Without it, researchers have suspected, we can't learn new memories or extinguish old ones to make room for new, less harmful ones.

Previous studies have linked mutations in the AKT gene to a host of problems, from schizophrenia and post-traumatic stress disorder to autism and Alzheimer's.

But, as Hoeffer's previous research has discovered, not all AKTs are created equal:

Different flavors, or isoforms, function differently in the brain. For instance, AKT2 found exclusively in the star-shaped brain cells called astroglia, is often implicated in brain cancer.

AKT3 appears to be important for brain growth and development. And AKT1, in combination with AKT2 in the prefrontal cortex of the brain, appears to be critical for learning and memory.

"These subtle differences could be really important if you wanted to personalize treatments for people," explains Marissa Ehringer, an associate professor of integrative physiology who partnered with Hoeffer on some of the research.

Three years in the making, the study adds an important new wrinkle to the story. Following National Institutes of Health guidelines that in the past six years began to require researchers to include both male and female animals in studies, it looked closely at how different gendered mice responded to the loss of various AKT isoforms.

"We found the difference between males and females to be so great it became the focus of our work," Hoeffer said. "It was like night and day."

For instance, male mice whose AKT1 was functioning normally, were much better than those missing the protein when it came to "extinction learning" - replacing an old memory, or association, that's not useful any more. (Imagine letting go of the memory of your favorite route home from work because you've moved or disassociating a loud sound with danger).

For female mice, it didn't make much of a difference.

Far more research is needed and underway, but Hoeffer suspects many other key proteins in the brain share similar nuances - with different flavors serving different purposes or acting differently in men and women.

With one in five U.S. adults living with mental illness and women as much as four times as likely to experience mental illness during their lifetimes, he hopes that by disentangling all those nuances, he can move the dial toward better, safer treatments.

"To help more people suffering from mental illness we need much more knowledge about the difference between male and female brains and how they could be treated differently," Hoeffer said. "This study is an important step in that direction."

Credit: 
University of Colorado at Boulder

Unmatched dust storms raged over Western Europe during Ice age maximum

image: The story in brief.

Image: 
TiPES/HP

Every late winter and early spring, huge dust storms swirled across the bare and frozen landscapes of Europe during the coldest periods of the latest ice age. These paleo-tempests, which are seldom matched in our modern climate frequently covered Western Europe in some of the thickest layers of ice-age dust found anywhere previously on Earth. This is demonstrated by a series of new estimates of the sedimentation and accumulation rates of European loess layers obtained by Senior Research Scientist Denis-Didier Rousseau from Ecole Normale Supérieure in Paris, France, and colleagues. The work, which is published in Quaternary Science Reviews is part of the TiPES project on tipping points in the Earth system, coordinated by The University of Copenhagen.

In the study Denis-Didier Rousseau and colleagues reinterpreted layers in loess from Nussloch, Germany. Loess is a fine-silt-sized earth type found all over the world. It mainly consists of aeolian sediments, which is material transported by the wind from dry areas without vegetation such as deserts of any type, moraines, or dried-out river beds.

Within the aeolian sediments, darker layers of paleosol alternate within the loess layers. Every layer in the loess represents a shift in climatic conditions. At Nussloch the paleosols stem from periods of milder climate, called interstadials during the ice age. The aeolian layers were deposited during the cold periods and consist mainly of dust and silt from the dry riverbeds of the Rhine river.

Traditionally in the academic field of paleo-climate, it has been assumed that interstadial paleosols developed on top of the underlying layer, by accumulation when the shift to a relatively mild climate allowed a richer biology to flourish in the region.

Into the dust

But careful sampling and accurate dating of the loess sedimentation from Nussloch with luminescence and C14 by Denis-Didier Rousseau and colleagues have now shown that this is not the case. Instead, in Europe, paleosols developed down into the underlying layer, not on top of the dust.

"In Europe, the paleosols are being embedded in the aeolian deposits. And when you are considering this, you have to take into account the thickness of the paleosol when you evaluate the dust deposition. Then we found aeolian accumulation and sedimentation rates which are much more precise than they were previously," says Denis-Didier Rousseau.

From this, it has been possible to construct new age models and recalculate sedimentation rates and mass balance for European loess layers in a range of samples from Brittany, Northern France Eastward to Ukraine on an almost longitudinal transect.

Dustiest region on Earth

The results show, that during the last glacial maximum, Western Europe was dustier than China which has otherwise been presumed to be the dustiest region on Earth in the coldest periods of the ice ages.

The new estimations of ice age dust accumulation in Europe fit a range of climate model simulations. The result thus has the potential to aid the understanding of the abrupt warming and cooling periods during the ice ages called Dansgaard/Oeschger events which bear the marks of climate tipping points.

Credit: 
University of Copenhagen - Faculty of Science

Research catches up to world's fastest-growing plant

image: From left: Todd Michael and Joseph Ecker

Image: 
Salk Institute

LA JOLLA--(February 1, 2021) Wolffia, also known as duckweed, is the fastest-growing plant known, but the genetics underlying this strange little plant's success have long been a mystery to scientists. Now, thanks to advances in genome sequencing, researchers are learning what makes this plant unique--and, in the process, discovering some fundamental principles of plant biology and growth.

A multi-investigator effort led by scientists from the Salk Institute is reporting new findings about the plant's genome that explain how it's able to grow so fast. The research, published in the February 2021 issue of Genome Research, will help scientists to understand how plants make trade-offs between growth and other functions, such as putting down roots and defending themselves from pests. This research has implications for designing entirely new plants that are optimized for specific functions, such as increased carbon storage to help address climate change.

"A lot of advancement in science has been made thanks to organisms that are really simple, like yeast, bacteria and worms," says Todd Michael, first author of the paper and a research professor in Salk's Plant Molecular and Cellular Biology Laboratory. "The idea here is that we can use an absolutely minimal plant like Wolffia to understand the fundamental workings of what makes a plant a plant."

Wolffia, which is found growing in fresh water on every continent except Antarctica, looks like tiny floating green seeds, with each plant only the size of a pinhead. It has no roots and only a single fused stem-leaf structure called a frond. It reproduces similar to yeast, when a daughter plant buds off from the mother. With a doubling time of as little as a day, some experts believe Wolffia could become an important source of protein for feeding Earth's growing population. (It's already eaten in parts of Southeast Asia, where it's known as khai-nam, which translates as "water eggs.")

To understand what adaptations in Wolffia's genome account for its rapid growth, the researchers grew the plants under light/dark cycles, then analyzed them to determine which genes were active at different times of the day. (Most plants' growth is regulated by the light and dark cycle, with the majority of growth taking place in the morning.)

"Surprisingly, Wolffia only has half the number of genes that are regulated by light/dark cycles compared to other plants," Michael says. "We think this is why it grows so fast. It doesn't have the regulations that limit when it can grow."

The researchers also found that genes associated with other important elements of behavior in plants, such as defense mechanisms and root growth, are not present. "This plant has shed most of the genes that it doesn't need," Michael adds. "It seems to have evolved to focus only on uncontrolled, fast growth."

"Data about the Wolffia genome can provide important insight into the interplay between how plants develop their body plan and how they grow," says HHMI Investigator and Professor Joseph Ecker, who is also director of Salk's Genomic Analysis Laboratory and a coauthor of the paper. "This plant holds promise for becoming a new lab model for studying the central characteristics of plant behavior, including how genes contribute to different biological activities."

One focus of Michael's lab is learning how to develop new plants from the ground up, so that they can be optimized for certain behaviors. The current study expands knowledge of basic plant biology as well as offers the potential for improving crops and agriculture. By making plants better able to store carbon from the atmosphere in their roots, an approach pioneered by Salk's Harnessing Plants Initiative, scientists can optimize plants to help address the threat of climate change.

Michael plans to continue studying Wolffia to learn more about the genomic architecture of plant development by using this simplified plant to understand the networks that control fate.

Credit: 
Salk Institute

Early functional SARS-COV-2 specific T cell response may prevent severe infection

Humoral and cellular adaptive immunity are two immune mechanisms that act against pathogens. Humoral immunity is mediated by antibodies, while cellular immunity does not involve antibodies and is, instead, facilitated by T cells. Studying how these immune mechanisms mediate SARS-CoV-2 infections could be beneficial in controlling the progression of the disease. However, their roles in viral control or disease pathogenesis is not fully understood and only a few studies have thoroughly monitored COVID-19 patients longitudinally, especially during the acute phase of infection.

To fill this knowledge gap, the team of researchers at Duke-NUS investigated the changes in virological and immunological parameters in 12 patients with symptomatic acute SARS-CoV-2 infection from onset of the disease to recovery or death.

"We found that patients who control SARS-Cov-2 infection with only mild symptoms are characterised by an early induction of IFN-γ secreting SARS-CoV-2 specific T cells. The amount of humoral response, however, does not predict the level of COVID-19 disease severity," said Dr Anthony Tanoto Tan, Senior Research Fellow at the Duke-NUS' Emerging Infectious Diseases (EID) programme and the co-author of this study.

"Our data supports the idea that SARS-CoV-2 specific T cells play an important role in the rapid control of viral infection and eventual clearance of the disease," added Dr Martin Linster, Senior Research Fellow with Duke-NUS' EID programme and the co-author of this study.

This work is a continuation of the team's previous publication in Nature, where they analysed SARS-CoV-2 specific T cell response in COVID-19 patients at convalescence. In this study, they have expanded the analysis to the full timeline of SARS-CoV-2 infection from onset to outcome.

"It is time that T cell monitoring should be considered in providing a comprehensive understanding of the immune response against SARS-CoV-2. This would also mean that a vaccine will likely be more effective if a holistic induction of both antibodies and T cells occurs," said Professor Antonio Bertoletti, from Duke-NUS' EID programme, who is the corresponding author of this study.

"This important study furthers our understanding of the immune response against SARS-CoV-2. It has far-reaching implications including on COVID-19 vaccine design and the subsequent monitoring of vaccine response," said Professor Patrick Casey, Senior Vice-Dean for Research at Duke-NUS.

The team is now studying more symptomatic COVID-19 patients with varying disease severity to further validate their findings.

Credit: 
Duke-NUS Medical School

Supersaturation: The barrier between protein folding and misfolding

image: Snake puzzle models of protein folding and amyloid fibril formation. Protein folding under Anfinsen's dogma leads to a unique functional native structure. Protein misfolding out of Anfinsen's dogma leads to amyloid structures. The two reactions are separated by the high free energy barrier of supersaturation. Once this barrier is broken by agitation or seeding, the equilibrium of folding and misfolding will be achieved.

Image: 
Osaka University

Correct, or native, protein folding is essential for correct protein function. Protein misfolding can lead to the formation of amyloid fibrils, and amyloidosis, which is implicated in various human neurodegenerative diseases, including Parkinson's, Alzheimer's, and Huntington's diseases. In this study Yuji Goto and colleagues describe, for the first time, a dynamic link between protein folding and misfolding, and the threshold that must be overcome for the formation of amyloid fibrils.

Technological advances are at the forefront of many scientific discoveries. The atomic structures of some amyloid fibrils were recently revealed as a result of advances in solid-state nuclear magnetic resonance and cryogenic electron microscopy. While an important step forward for the field, this development does not fully explain the determining factors of protein misfolding. How are folding and misfolding related? Can folding/unfolding and amyloid polymerization/depolymerization be explained by a single mechanism, and if so what might this look like? These are the questions that researchers at Osaka University sought to answer.

Summarizing their motivation for this work, senior author Masahiro Noji explains: "The thermodynamic hypothesis of protein folding, known as the 'Anfinsen's dogma' describes that the native structure of a protein represents a free energy minimum determined by the amino acid sequence. However, this is not consistent with the misfolding of globular proteins to form amyloid fibrils." Therefore, Yuji Goto and colleagues set out to explore the link between protein folding and misfolding.

Although proteins perform their functions by folding to their native structures, as represented by Anfinsen's dogma, proteins often misfold to form amyloid fibrils, leading to amyloidosis. In their paper, the research team from Osaka University describe a general concept for the link between protein folding and misfolding.

"The supersaturation barrier of a denatured protein separates protein folding and amyloid formation, and misfolding occurs when this barrier breaks down" corresponding author Yuji Goto says. "Our results show a clear link between correct protein folding, as defined by Anfinsen's dogma, and protein misfolding."

Supersaturation can be observed throughout nature in the formation of crystals, including those involved in ice formation. Here, the team at Osaka University show that supersaturation is fundamental to correct protein folding. The supersaturation barrier represents a novel concept that will advance the field of protein folding and contribute to the development of therapeutic strategies to prevent and treat amyloidosis, including those involved in neurodegenerative diseases.

Credit: 
Osaka University

Batteries that can be assembled in ambient air

image: Battery production in ambient air using a multi-functional separator

Image: 
POSTECH

The honor of the 2020 Nobel Prize in Chemistry went to those who developed lithium-ion rechargeable batteries. These batteries have become an essential energy source for electronic devices ranging from small IT devices to electric vehicles. Tesla, a leading U.S. automaker, recently emphasized the need to establish an innovative production system and reduce battery cost. The price of batteries accounts for a large portion of electric vehicles and cost reduction is vital to popularizing them.

A joint research team, led by Professor Soojin Park and Ph.D. candidate Hye Bin Son of POSTECH's Department of Chemistry with Professor Seungmin Yoo of Ulsan College, has successfully developed a multi-functional separator which allows the batteries to function even when the pouch cell is assembled in ambient air. These findings were introduced in the latest online edition of Energy Storage Materials.

Since the electrolyte inside the battery reacts with moisture to cause deterioration, lithium-ion batteries are typically assembled in a dry room which maintains less than 1% humidity levels. However, maintaining a dry room is rather costly.

To solve this issue, studies have been conducted to suppress impurities - such as moisture or hydrofluoric acid - by injecting additives into the electrolytes. But these can cause unwanted side reactions during the battery operation. In fact, when batteries are activated at a high temperature (50? or higher), even a small bit of moisture causes faster performance deterioration. Therefore, there is a need for a material capable of trapping moisture and impurities in the battery without adverse electrochemical reactions to the additives.

To this, the joint research team introduced functional materials that can trap impurities on the surface of the separator to increase thermal stability and improve battery performance. This multi-functional separator demonstrated excellent heat resistance (shrinkage within 10% after 30 minutes of storage at 140?. Conventional separator had 50% shrinkage) and further showed improved electrochemical performance at the high temperature of 55? (79% of the initial capacity maintained after 100 charging cycles).

Additionally, the researchers confirmed the effectiveness of the functional material in the electrolyte in the impurity-filled environment. The silane compound on the surface of the synthesized functional ceramic traps moisture and maintains the ceramic structure well, but the general ceramic material was corroded by the acidified electrolyte. Moreover, through this research, the team confirmed that this multi-functional separator produced in the ambient air this time exhibits superior lifespan than the conventional separators, confirming that it provides stable performance beyond the role of a simple separator.

"This newly developed multi-functional separator shows great stability and excellent electrochemical performance at high energy density," remarked Professor Soojin Park who has long been studying battery separators through various approaches. "With this first successful case of fabricating batteries in ambient air, it is expected to play a big role in reducing battery cost."

Credit: 
Pohang University of Science & Technology (POSTECH)

Easily assembled gold nanoparticle scaffolding serves as molecular probe

image: One-step preparation of photoaffinity probes using clickable gold-nanoparticle precursors enables expedient target identification studies

Image: 
FIGURE MODIFIED FROM Organic and Biomolecular Chemistry, January 2021, DOI: 10.1039/D0OB01688H

The development of pharmaceutical treatments is difficult -- clinicians and researchers know a certain drug can regulate particular functions, but they might not know how it actually works. Researchers at Tokyo University of Agriculture and Technology (TUAT) have developed a new, streamlined method to better understand the molecular mechanisms underpinning these interactions.

They published their approach on Dec. 17, 2020 in Organic & Biomolecular Chemistry, a journal of the U.K. Royal Society of Chemistry.

"We set out to develop a new gold nanoparticle-based method for target identification of bioactive small molecules that streamlines the current laborious steps so that we can rapidly find out how these molecules work," said Kaori Sakurai, associate professor in the Department of Biotechnology and Life Science at TUAT.

Bioactive small molecules are chemical compounds, such as pharmaceuticals, that can be readily delivered to and interact with a body's cells. By binding to specific proteins, these molecules can rewire a biological process to stop or enhance whatever the initial function was. For example, the bioactive small molecules in an anticancer agent will bind with a protein in cancer cells to inhibit their uncontrolled growth. They can even to trick the cancer cells into programmed cell death.

The challenge is that it's not always clear which proteins are being targeted or whether there are other proteins targeted that may potentially cause unwanted side effects. Using a technology called photoaffinity labeling, researchers can shine light on target proteins and instantaneously tag them, capturing and identifying them. However, photoaffinity labeling requires extensive time and resources to develop the specific tag, ensure it is attached to the right target in the cell and then purify the tagged target protein.

"Photoaffinity labeling is a powerful approach for the discovery of small molecule-target proteins," Sakurai said. "However, its routine use has been hampered by several issues, including inefficient protein labeling and subsequent purification and technical difficulties of making bioactive small molecules into suitable probes."

Sakurai's team previously provided a solution to the first issue by employing a gold nanoparticle as modular scaffolding on which a specific probe can be designed. In the recent paper, they focused on developing a one-step preparation process.

Since gold nanoparticles have surfaces that can hold modular pieces, the researchers can efficiently build customized assemblies by simply mixing building blocks, according to paper co-author Kanna Mori, a graduate student in the Department of Biotechnology and Life Science at TUAT.

"Photoaffinity probes can be easily obtained from the probe precursors, preassembled with three types of building blocks -- each containing a clickable group, a photoreactive group and a water-soluble spacer group--and then rapidly incorporate a small-molecule of interest through 'click chemistry,'" Mori said.

The fabricated small molecule, even after being conjugated to the nanoparticle, behaves as a parent molecule that would naturally bind to a protein, and the photoreactive group reacts to ultraviolet light irradiation that activates the probe. Once activated, the probe can capture and isolate a target protein.

"We demonstrated that clickable photoaffinity probe precursors will provide a rapid access to photoaffinity probes of different types of bioactive small molecules to identify their target proteins," Sakurai said.

Next, the researchers plan to explore the utility of gold-nanoparticle probes in target identification studies in live cells, expanding their work to factor in physiological conditions. They also plan to introduce complex natural products and some pharmaceuticals into the gold-nanoparticles to begin identifying their unknown target proteins.

Credit: 
Tokyo University of Agriculture and Technology

Socioeconomic, demographic and urban factors influence the spread of COVID-19

Per capita income, population volume and density, the structure of cities, transport infrastructure or whether districts have their own schools are all factors that can affect the spread of COVID-19. This has been confirmed by a study carried out in 73 districts in Barcelona by researchers from the departments of Geography and Economics of the Universitat Rovira i Virgili, the results of which have been published in the Journal of Public Health. The research reveals that the analysis of the characteristics of every district can facilitate decisions on the specific measures to be applied to individual districts in an attempt to effectively reduce the rate of infection.

To carry out the study, the researchers analysed the data provided by the Public Health Agency of Barcelona on the 41,606 people who were infected with the coronavirus during the first two waves of the pandemic in the 73 districts of the capital. Work was done in two different time periods to differentiate the two waves: the first was from 26 February to 15 July and the second was from 16 July to 16 October. This information showed how the individuals in the city were distributed and whether the positive cases followed some sort of territorial pattern in the sense that levels would be low or high in neighbouring districts.

The study found that the characteristics of every district had a direct impact on the spread of the virus. "The results of the model are clear: particular characteristics show that the virus has particular effects in both waves: for example, the higher the population density is, the more cases there are, and the higher the average income is, the fewer cases there are," explains Josep Maria Arauzo, professor of the URV's Department of Economics and one of the authors of the study.

But the study also shows that in the two waves the collective behaviour of the population was different, which may explain why the virus spread differently in different areas. In this regard, the population structure plays a key role since in the first wave the percentage of positive cases was highest among senior citizens. However, as soon as greater social interaction was allowed and the shortcomings of managing nursing homes had been detected, the highest numbers of infections were found in those districts with a younger population while the number of infections in districts with older populations decreased. "We also observed that the presence of educational institutions increased the number of infections, not because of organisational in these institutions but because of the interactions that took place outside them," points out Aaron Gutiérrez, a researcher from the URV's Department of Geography.

"The study shows the importance of taking local differences into account when adopting measures to efficiently combat the pandemic since if the same measures are applied equally in all places these differences will mean that their effects are quite different," concludes the researcher Antoni Domènech.

Credit: 
Universitat Rovira i Virgili

Co-use of alcohol and marijuana and beliefs among teens

New research from the Prevention Research Center of the Pacific Institute for Research and Evaluation examines whether recreational marijuana legalization in Oregon and marijuana and alcohol retail outlet density levels are associated with co-use and beliefs supportive of use of each among teens.

Using data from 11th graders who participated in the Student Wellness Survey from 2010-2018, researchers assessed past-30-day co-use changes in counties with low, medium, and high densities of licensed marijuana and alcohol outlets.

Findings include:

A significant post-legalization increase in past-30-day co-use in 2016 in counties with the highest retail outlet density.

Significant post-legalization increases in perceived risk and parent approval of alcohol and marijuana use.

Legalization and greater retail availability of both marijuana and alcohol were positively associated with co-use among teens, and beliefs favorable to alcohol and marijuana use.

Says lead author, Dr. Grisel García-Ramírez: "Our results suggest that adolescents living in communities with greater retail availability of recreational marijuana and alcohol may have greater indirect access to these substances through diversion, as it is illegal for them to purchase and use them. So, their primary sources are likely to be social rather than commercial."

Credit: 
Pacific Institute for Research and Evaluation

LCMC3: Neoadjuvant atezolizumab safe, meets primary endpoint of pathologic response rate

(Singapore--January 30, 2021 11:00 p.m. SPT/January 30, 2021 10:00 a.m. EST)-- Primary analysis of the Lung Cancer Mutation Consortium (LCMC) 3 study revealed that neoadjuvant atezolizumab prior to lung cancer surgery was well tolerated by patients and met its primary endpoint of 20% major pathologic response rate, according to research presented today at the International Association for the Study of Lung Cancer's World Conference on Lung Cancer.

Dr. Jay M. Lee, chief, Division of Thoracic Surgery at Ronald Reagan UCLA Medical Center in Los Angeles, today reported on results from a study of 181 patients with stage IB to IIIB non-small cell lung cancer (NSCLC) who each received 1,200 mg of neoadjuvant atezolizumab intravenously every three weeks for two cycles followed by resection. Atezolizumab is a monoclonal antibody that was approved by the US Food and Drug Administration in 2020 for the first-line treatment of adult patients with metastatic NSCLC.

Dr. Lee reported earlier that small pilot studies (N Engl J Med. 2018;378:1976) have shown preoperative immune checkpoint inhibitor therapy may be of benefit in resectable NSCLC. Dr. Lee stated that "the LCMC3 study is the largest, monotherapy trial of checkpoint inhibition in resectable NSCLC and is a landmark study to compare future results."

Patients received neoadjuvant atezolizumab for two cycles, followed by resection between 30 and 50 days from the first cycle. Patients who benefitted from the therapy continued adjuvant atezolizumab for 12 months. The primary endpoint was major pathologic response (MPR; less than or equal to 10% viable tumor cells at surgery) in patients without EGFR or ALK mutations.

Of the 181 patients enrolled, the median age was 65 years; 51% were female, 90% were current/former smokers, and 62% had a nonsquamous histology. Patients were categorized in the following stages: 17 patients were staged at IB; 20 were IIA, 55 were IIB, 72 were IIIA, and 17 were IIIB.

In patients without EGFR/ALK mutations who underwent surgery, the major pathologic response rate was 21% (30/144; 95% CI: 14%-28%) and the pathologic complete response rate was 7% (10/144; 95% CI: 3%-12%).

"It is important to recognize that the preoperative and intraoperative unresectability rates in LCMC3 are comparable to historical neoadjuvant chemotherapy trials and should not raise concern," said Dr. Lee. Following atezolizumab, unresectability was detected preoperatively in only 22 out of 181 (12%) and intraoperatively in 7 out of 159 (4%). The majority of patients (151/159; 95%) had anatomic oncologic resections and only 15 out of 101 (15%) converted to thoracotomy. Pathologic downstaging was seen in 66 out of 155 (%). Only 19 out of 159 (12%) had surgery outside of protocol window.

Intraoperative complications were rare (5/159; 3%) and 145 out of 159 (92%) had complete (R0) resection. Postoperative adverse reactions correlated with fewer viable tumor cells in the resected specimen. Mortality for 30 days and 30 to 90 days were each 1 out of 159 (0.6%).

"Following neoadjuvant atezolizumab, resection was performed safely with low perioperative morbidity and mortality soon after completion of neoadjuvant therapy, infrequently outside of the protocol window, and with high complete resection rates," Dr. Lee said. "These findings represent the primary analysis of the completed LCMC3 study and are consistent with our previous results, including a preliminary report on a portion of these patients [in] 2019."

"The integration of immunotherapy and targeted therapies in the multidisciplinary approach of early-stage NSCLC represents a priority," said Dr. Scagliotti, interim IASLC CSO. "The IASLC is currently engaged in fostering the international collaboration through multiple initiatives."

Credit: 
International Association for the Study of Lung Cancer

ERAS program expedites recovery for congenital heart surgery patients

CHICAGO (January 30, 2021) -- Select patients born with heart defects and who undergo congenital heart surgery recover with few complications and reduced opioid use when a comprehensive, evidence-based enhanced recovery after surgery (ERAS) program is used, according to research presented at the 57th Annual Meeting of The Society of Thoracic Surgeons.

"We have embarked on a new paradigm for patient care with the goal of improving recovery, patient experience, and the value of care that we provide," said Nathalie Roy, MD, from Boston Children's Hospital in Massachusetts. "The early findings show promise that such programs can be a game-changer in cardiovascular care."

Dr. Roy and colleagues collected data from eligible patients who had elective surgery for simple or moderately complex congenital heart defects at Boston Children's Hospital from October 2018 to February 2020. During the study period, 559 patients underwent congenital heart surgery as part of a protocol-driven, multidisciplinary ERAS cardiac surgery program. The ERAS patients were identified before surgery, while the decision to remain in the program was based on surgical results.

The patient outcomes were reviewed by implementation period (P1): October 2018 to February 2019, and the early experience period (P2): March 2019 to February 2020.

Overall, researchers found that several factors significantly improved from P1 to P2, as the program became more sophisticated and advanced with time, familiarity, and experience. The study showed an increase in operating room extubation, which is the removal of the breathing tube, with 27% of P2 patients being extubated in the OR versus 16% of P1 patients. Patients in the P2 group also experienced shorter ventilation time in the intensive care unit (ICU): 6.1 hours for P2 versus 7.6 hours for P1.

In general, the ICU and postoperative lengths of stay were not significantly different between the two groups, except in the case of lower-risk procedures. Congenital heart operations are grouped by complexity of the procedure in what is known as STAT Categories. STAT Category 1 includes the least complex operations, and STAT Category 5 includes the most complex operations. For STAT Category 2 operations, fewer hours were spent in the ICU: 25.7 hours for P2 patients versus 34.6 hours for P1.

Importantly, the data also demonstrated excellent pain control with an opioid-sparing approach that included adjunct medications and regional anesthetic approaches in certain cases. Reducing opioid utilization has potential benefits for quickening recovery, while research studying regional anesthesia is ongoing at Boston Children's Hospital.

Further, the study showed steady low rates of complications, reoperations, or readmissions.

"Our program defined a comprehensive approach of care throughout the surgical journey," said Dr. Roy. "We were able to remove the breathing tube earlier after surgery and manage pain well with opioid-sparing strategies--these are key components of an enhanced recovery program after congenital cardiac surgery."

ERAS is a set of predetermined activities, steps, and guidance designed to achieve quicker recovery and the best possible outcomes for patients undergoing major surgery. First popularized in Denmark in the 1990s, it since has become more accepted. Over the past several years, ERAS protocols have been incorporated into many surgical specialties, with congenital heart surgery now joining the movement.

"ERAS has been shown to improve important metrics in perioperative surgical care and result in beneficial patient outcomes," said Lauren C. Kane, MD, from Children's Hospital New Orleans in Louisiana, who was not directly involved in this research. "Through the work of Dr. Roy and colleagues, using ERAS programs with pediatric and adult congenital heart patients is closer to universal adoption throughout the country."

Even with the encouraging early results of this step-based approach, the researchers acknowledged that there still is much to do. For example, despite using this comprehensive ERAS program, compliance and use were not optimal for all steps of the program. The challenges of introducing new protocols in a large institution are many, but the regular feedback reviews with multidisciplinary team members are critical to improving the program, compliance, and provider acceptance. In addition, empowering patients and their families by providing education before and throughout the program also is important.

However, this ERAS program, in the early stages, showed promise for decreased variability in care, the optimization of resource use, and expedited recovery after surgery--all of which ultimately have the potential to enhance overall family and patient experiences and improve patient outcomes.

Launched in 2018, the ERAS Cardiac Program at Boston Children's Hospital involves all phases of the patient's surgical care, from before surgery to at-home postsurgical follow-up. The program offers important strategies such as less fasting, multiple approaches to treat pain, smaller surgical incisions when appropriate, blood conservation, early extubation, removal of lines, tubes, and catheters as soon as possible, getting out of bed early after surgery, and a quick return to a normal diet. Expanded surgical follow-up with early virtual visits and patient reported outcomes surveys to monitor for complications also are included in the program.

The Boston Children's ERAS program continues to evolve based on feedback collected in monthly quality improvement meetings. In addition, in order to help enable lasting programmatic improvements, Dr. Roy and colleagues created an interactive dashboard, which is connected to the Boston Children's Hospital ERAS Database. The dashboard, updated in real time, allows visualization of performance metrics that can be filtered by parameters such as age group and surgical complexity for in-depth analyses.

"An ERAS program requires institutional commitment and stakeholder involvement at all levels of the heart center," said Dr. Roy. "In congenital cardiac surgery, our program is in its early phase. Data are promising, but more research is needed, especially related to specific components of care for which there sometimes is low evidence in this population."

Future studies and ongoing efforts by the researchers will focus on pain and opioid-sparing strategies, factors associated with postoperative nausea and vomiting, the effects of transfusions on outcomes, and prehabilitation.

Credit: 
The Society of Thoracic Surgeons

'COVID effect' leads to fewer heart surgeries, more patient deaths

CHICAGO (January 30, 2021) -- The most deadly global health crisis in a century has resulted in a substantial decline in overall heart surgery volume and an unexplained increase in deaths after coronary artery bypass grafting, according to late-breaking research presented at the 57th Annual Meeting of The Society of Thoracic Surgeons.

"This study was a true herculean analysis and tour de force that showed the COVID effect on adult cardiac surgery volume, trends, and outcomes," said Tom C. Nguyen, MD, from the University of California San Francisco. "The pandemic has changed the world as we know it, causing a dramatic drop in adult cardiac surgery volume and worsening patient outcomes."

Dr. Nguyen and colleagues queried the STS Adult Cardiac Surgery Database from January 1, 2018, to June 30, 2020, and The Johns Hopkins COVID-19 Dashboard from February 1, 2020, to January 1, 2021. The researchers examined data from 717,103 adult cardiac surgery patients and more than 20 million COVID-19 patients in an effort to determine how the pandemic affected adult cardiac surgery on national and regional levels.

"Only the STS National Database has the level of granularity, COVID variables, and longitudinal follow-up to answer the questions posed in this important study," said Dr. Nguyen. "Our research also analyzed data by regions to get an idea of how specific areas did during the COVID pandemic."

According to the study results, there was a 53% decrease nationwide in all adult cardiac surgery volume when compared to 2019 and 65% fewer elective cases in the United States. COVID also impacted non-elective cases, resulting in a 40% decrease.

In addition, the data showed that no matter the procedure--isolated coronary artery bypass grafting (CABG), isolated aortic valve replacement (AVR), isolated mitral valve replacement (MVR), CABG+AVR, CABG+MVR, isolated MV repair, and CABG+MV repair--there was a significant decline in case volume--54%--when compared to 2019.

Regionally, the Mid-Atlantic area (New York, New Jersey, and Pennsylvania), was among those most affected by the COVID crisis, experiencing a 71% decrease in overall case volume, 75% fewer elective cases, and a 59% reduction in non-elective cases. Another hotspot, the New England region (Maine, Vermont, New Hampshire, Massachusetts, Connecticut and Rhode Island), showed a 63% reduction in overall case volume.

The researchers also found that prior to the COVID surge, the Mid-Atlantic and New England regions had excellent outcomes with an observed-to-expected (O/E) ratio of less than 1, which represents a better-than-expected mortality rate. However, during the COVID surge, there was a 110% increase in the O/E for all adult cardiac procedures and a 167% increase for isolated CABG, meaning more patients were dying than expected.

Though the data did not directly address the cause of increased mortality, many surgeons say they currently are limited to operating on only the most urgent coronary bypass cases and patients who tend to be sicker. "These numbers should not serve as a deterrent to patients seeking care for chest pain or other cardiac symptoms," said Robbin G. Cohen, MD, MMM, from Keck School of Medicine of the University of Southern California in Los Angeles, who was not directly involved with this study. "If anything, they are a warning to get into the system as soon as possible."

At the time of presentation, there were 95.4 million global cases of COVID-19 with more than 2 million global deaths. The US accounted for more than 24 million cases and approximately 400,000 deaths.

In the past year, this crisis has altered or halted virtually every aspect of society, and the practice of cardiothoracic surgery clearly has not been immune. The abrupt cessation of surgery in mid-March 2020 has proven to have had far-reaching implications, as the negative effects of canceled and postponed procedures on patient health outcomes now are being realized.

"We clearly demonstrated that if you have heart surgery during COVID, you have an increased risk of morbidity and mortality," said Dr. Nguyen. "No doubt that COVID hit us hard."

According to Dr. Nguyen, this study is only the first of many more "granular" analyses to come. The researchers plan to examine trends and outcomes of COVID patients vs. non-COVID patients, as well as delve more into the COVID effect on specific adult cardiac procedures such as aortic dissections.

Credit: 
The Society of Thoracic Surgeons

Reindeer lichens are having more sex than expected

image: Reindeer lichen

Image: 
Marta Alonso-García

In northern Canada, the forest floor is carpeted with reindeer lichens. They look like a moss made of tiny gray branches, but they're stranger than that: they're composite organisms, a fungus and algae living together as one. They're a major part of reindeer diets, hence the name, and the forest depends on them to move nutrients through the ecosystem. They also, at least in parts of Quebec, are having a lot more sex than scientists expected. In a new study in the American Journal of Botany, researchers found that the reindeer lichens they examined have unexpected levels of genetic diversity, indicating that the lichens have been doing more gene-mixing with each other than the scientists would have guessed.

"We were surprised because this species of reindeer lichen had always been considered mainly a clonal species that reproduces asexually," says Marta Alonso-García, the paper's lead author and a postdoctoral fellow at Quebec's Université-Laval. "It doesn't follow the expected pattern."

Reindeer lichens swing both ways: they can reproduce sexually via spores, or they can asexually clone themselves. When fungi reproduce sexually, they send out root-like structures toward a neighboring fungus and exchange genetic information when they touch. They then release spores, single cells containing genetic material, which travel on the wind and disperse. When they land, they start growing and produce a new baby fungus that's genetically distinct from its parents. In asexual clonal reproduction, on the other hand, a piece of the entire lichen (fungus and alga), called the thallus, is pinched off and regrows into a whole organism that's genetically identical to its parent.

The two reproductive methods have different advantages. "Sexual reproduction is very costly," says Felix Grewe, the co-director of the Field Museum's Grainger Bioinformatics Center and a co-author of the study. "You have to find your partner, it's more difficult than reproducing asexually. But many organisms do it because when you have this combining and mixing of genetic traits, it enables you to weed out negative mutations long-term among other benefits."

The researchers were examining reindeer lichens (Cladonia stellaris) to learn about their genetic patterns. "We used DNA sequences to tease apart the genetic relationships between populations of this lichen," says Alonso-García. "We tested whether individuals from northern Quebec (Hudson Bay) were genetically different from those from the South (Parc National des Grands-Jardins, two hours from Québec City). At the same time, due to its important role in the colonization process after a fire, we evaluated lichen genetic diversity along a post-fire succession."

Lichens can reveal a lot about how wildfires affect ecosystems. "Wildfire is the most significant disturbance in the world's northernmost forests, and it plays a major role in determining the distribution and composition of plant communities," says Alonso-García. "In Eastern North America, four successional vegetation stages are generally identified after a fire. During the first stage, crustose lichens and mosses colonize the burned surface. Subsequently, the soil is covered by cup and horn lichens. The landscape remains mostly uniform for around 20 years until the arrival of fruticose lichens which replace the previous vegetation. Cladonia stellaris arrives the last one, usually three or four decades after fire." By studying genetic variations in reindeer lichens, the researchers hoped to learn how lichens recolonize an area after a fire.

To study the lichens' DNA, the researchers ground up samples of lichens and extracted their DNA. But lichens present an extra challenge in this process, since they're made up of a fungus and an alga (or a kind of bacteria that performs photosynthesis) living together. "That means that all the DNA is mixed up together, we get one pool that contains fungal DNA and algal DNA," says Grewe. "We have to carefully filter and sort the sequence reads bioinformatically." The main body of a lichen is made up of the fungus, so the researchers wanted to focus on the fungal component's DNA. By comparing the pool of DNA to existing genomes, the researchers were able to pick out the DNA belonging to the fungus, and they could then compare the fungal DNA from reindeer lichens from different areas of Quebec.

What they found was surprising: in general, there was a lot more genetic variation in the lichens than the researchers expected, and that indicates hanky-panky. "It's a general assumption was that these reindeer lichens mainly reproduce asexually because there's little evidence for them producing spores, but now the genetic data shows all this diversity, and that leads to the assumption that might be some form of sex," says Grewe.

"We were expecting that lichens from North Quebec would be more similar to each other than to those from Parc National des Grands-Jardins. However, our results suggest constant migration of C. stellaris between populations throughout Eastern North America," says Alonso-García. "In fact, contrary to the widespread belief, we found many reproductive structures in the species and these structures are formed after sexual reproduction."

But while the lichens are apparently doing more genetic intermingling than expected, the researchers also found that after a forest fire, the new lichens that crop up are genetically similar to the ones that were there before. That was counterintuitive-- the thought had been that the little cloned lichen bits would be destroyed in a fire, and that the repopulation of lichens would be growing from spores that arrived on the wind from other areas. "Regarding the genetic diversity of the species after fires, we found no differences along four stages of the succession. This was also astonishing because time since the last fire increases the probability that clonal fragments successfully reached the sites, enhancing genetic diversity," says Alonso-García.

In addition to revealing the hidden sex lives of reindeer lichen, the study could have implications for forest conservation. "We have learned that time since the last fire does not necessarily mean more genetic diversity, so conservation strategies in boreal forests should take this into account," says Alonso-García. "Prioritizing the protection of an area should not be based exclusively on its age. This is quite important because funding is usually limited, so we cannot carry out conservation activities in the entire forest." In short: if conservation scientists want to protect areas of forest with genetically diverse lichen populations, the forest's age isn't the only indicator of diversity.

Grewe adds the importance of bioinformatics in learning about how organisms are related to each other. "It is astonishing that today we can have such a detailed view of the evolution of populations using bioinformatics," says Grewe. "This is another good example of how advancement in sequencing technology allows us to learn about the evolution of an organism in more detail than ever before."

Credit: 
Field Museum

Accurate drug dosages with proton traps

image: Daniel Simon, associate professor in the Laboratory of Organic Electronics, Department of Science and Technology at Linköping University.

Image: 
Thor Balkhed

Researchers at Linköping University, Sweden, have developed a proton trap that makes organic electronic ion pumps more precise when delivering drugs. The new technique may reduce drug side effects, and in the long term, ion pumps may help patients with symptoms of neurological diseases for which effective treatments are not available. The results have been published in Science Advances.

Approximately 6% of the world's population suffer from neurological diseases such as epilepsy, Parkinson's disease, and chronic pain. However, currently available drug delivery methods - mainly tablets and injections - place the drug in locations where it is not required. This can lead to side effects that harm the patient.

"Organic electronic ion pumps have a huge potential for use in the treatment and diagnosis of neurological diseases. They could function in a similar manner to the insulin pumps already in use, but deliver the drug directly into the nervous system. Our most recent discovery is a proton trap that makes the amount delivered even more precise", says Daniel Simon, associate professor in the Laboratory of Organic Electronics, Department of Science and Technology at Linköping University.

Daniel Simon's research group has previously developed an organic electronic ion pump with delivery outlets as small as 20 x 20 micrometres. It should be possible to implant such devices to deliver drugs at exactly the desired location in the nervous system. The scientists hope that it will be possible to use the ion pump to discover and halt the development of neurological symptoms before the patient notices them.

Previous experiments were carried out on slices of mouse brain, using the naturally occurring signal substance GABA (gamma aminobutyric acid) as active drug. GABA is an inhibiting signal substance naturally found in the brain. When the amount of GABA increases, nerve cells are less likely to transfer nerve impulses to the next cell. A neurological seizure, such as occurs in epilepsy, in which the brain's nerve cells become overactive, is in this way prevented. When the ion pump is configured to transport GABA from an electrolyte reservoir outside the body to the desired location in the nervous system, a small voltage is used, which "pumps" the positively charged GABA through a transport channel. The method is known as electrophoresis. However, positive hydrogen ions, protons, from the electrolyte solution accompany the GABA through the channel. This leads to imprecise dosage and a drop in the pH of the tissue (making it more acidic), which can cause side effects.

The research group at Linköping University has now improved the ion pump. By introducing proton traps along the transport channel, the number of protons that pass can be considerably reduced. The proton trap consists of palladium, a noble metal that reacts readily - and nearly exclusively - with hydrogen and thus captures the positively charged protons. The proton traps mean that the ion pump can deliver a more precise dosage of the drug, since the potential applied corresponds almost exactly with the amount of GABA transported by the electrophoresis process.

"I believe that in a few years we will see organic bioelectronic ion pumps being used in the treatment of many neurological diseases. The proton trap can be integrated into all organic bioelectronic ion pumps, and our discovery has brought practical applications a lot closer", says Xenofon Strakosas, staff scientist and co-first-author with Maria Seitanidou, postdoc, both at the Laboratory of Organic Electronics, of the article in Science Advances.

Credit: 
Linköping University

Radiation Oncology trials using PET with FDG uptake among NSCLC patients

(Singapore--January 29, 2021 9:35 a.m. SPT/January 28, 2021 8:35 p.m. EST)--Two radiation oncology trials presented at the IALSC World Conference on Lung Cancer Singapore highlight how some researchers are exploring use of higher radiation boost doses to only PET-positive regions in locally-advanced non-small cell lung cancer (NSCLC). A previous large RTOG phase III trial revealed that the unform delivery of a high dose to the entire tumor led to poorer survival.

In one study, Prof. Feng-Ming (Spring) Kong, Case Western Reserve University School of Medicine, in Cleveland, Ohio presented the results of a multicenter trial which aimed to determine whether adaptive isotoxic radiation dose escalation to mid-treatment FDG-PET provides superior local tumor control compared to a standard uniform dose of 60 Gy in patients with stage III NSCLC.

Prof. Kong and the research centers involved in the trials enrolled 138 patients with stage III NSCLC who were medically fit for concurrent chemoradiation. The patients were randomly assigned by a 1:2 ratio to standard (60 Gy) arm or to an adaptive-therapy arm, with dose individualized to 20 Gy mean lung dose (MLD), and adapted to residual tumor on the mid-treatment FDG-PET/CT. All patients had FDG-PET performed around 40 Gy mid-treatment, and radiation therapy was delivered in 30 daily fractions (Fx).

Of 138 patients enrolled between February 2012 and March 2017, 127 were eligible and analyzable, with 43 and 84 patients in the standard and adaptive arms, respectively, with a minimum follow-up of 3.7 and 3.4 years for surviving patients, also respectively.

The adaptive arm consisted of an initial plan of 2.2 Gy/Fx for 21 Fx followed by an adaptive radiation therapy boost to mid-treatment FDG-PET target using a variable prescription of 2.2-3.8 Gy/Fx for the final 9 Fx. The primary endpoint of this report was 2-year local-regional tumor progression free (LRPF), with inclusion of overall and in-field LRPF, assessed independently and blindly by radiologists.

There were no significant differences in lung, esophagus, and heart toxicities, though the adaptive arm had numerically higher mean doses of these organs at risk. The 2-year overall LRPF rates were 59.5% (95% CI: 37.9, 75.7) on the standard arm, and 54.6% (95% CI: 39.9, 67.0) on the adaptive arm. The median LRPF time was 27.5 months (95% CI: 14.3, not reached) on the standard arm and 28.4 months (95% CI: 19.1, not reached) on the adaptive arm. There were no significant differences in overall survival, progression-free survival, or lung cancer-specific survival between the two arms, according to the presentation by Dr. Kong.

"This is the first randomized trial that demonstrated the feasibility and safety of performing biologically adaptive radiation therapy escalation in a multicenter setting in patients with stage III NSCLC. This preliminary analysis did not show an improvement in overall local regional tumor control," Dr. Kong reported.

In the second study, Dr. Saskia Cooke, The Netherlands Cancer Institute in Amsterdam, Netherlands, reports on local and regional failure in the phase II PET-Boost trial (NCT01024829). In this study, patients with stage II-III non-small cell lung cancer (NSCLC) were treated with hypofractionated dose escalation to either the primary tumor as a whole (Arm A) or the high fluorodeoxyglucose (FDG)-uptake region inside the PT (> 50% SUVmax; Arm B).

The trial randomly assigned 107 patients--82% had stage III disease and most patients (72%) received concurrent chemoradiotherapy. In Arms A and B, median gross tumor volume (GTV) for the primary tumor was 100 and 115 cm3, respectively; median GTV for the involved lymph nodes was 18 and 20 cm3, respectively. Median fraction dose was 3.25 Gy to planning target volume (PTV) to the entire primary tumor and 3.50 Gy to PTV 50% SUVmax, resulting in total planned physical dose of 78.0 and 84.0 Gy, in 24 fractions. Median overall treatment time was 34 days in both arms, and median follow-up for CT scans in central review was 12.6 months.

In a previous report, the authors revealed that the primary tumor was non-measurable on follow-up in 27% of patients [Cooke S, 2020]. Of the 12 patients in Arm A who experienced locoregional failure, 2 had local failure (LF) without regional failure (RF) and 9 had RF without LF. Of the 15 patients in Arm B, 4 had LF without RF and 10 had RF without LF. In Arms A and B, respectively, the 2-year cumulative incidence of LF was 11% and 18%, and 28% and 25% for RF. The authors concluded that "dose escalation to the whole PT or 50% SUVmax in patients with NSCLC led to excellent local control rates in both treatment arms". However, few patients were evaluable for assessment of local failure at 2-years, grade 5 toxicity rates was previously reported to be 16% [van Diessen J, 2018], with 3-year OS rates of only 37% in armA and 33% in armB, respectively.

Credit: 
International Association for the Study of Lung Cancer